Further studies will be required to determine whether sarpogrelate treatment may improve micro- and macrovascular disturbances derived from experimental long-term T1D, in order to confirm whether the selective 5-HT2 receptor blockade is a key therapeutic target in the treatment and/or prevention of cardiovascular complications resulting from chronic hyperglycaemia. This evidence concerns the gene HTR2A and Hyperglycemia.